App-Quantinova.ai

Real world experience with nivolumab in Indian patients with metastatic renal cell carcinoma: A single centre experience.

Amit Rauthan - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Therapeutic benefit of empiric drug sequencing in metastatic renal cell carcinoma.

Viola Chen - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Predictors of progressive disease (PD) and subsequent outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo).

Haris Zahoor - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Nivolumab

Early assessment by FDG PET/CT to predict short-term outcome in clear cell renal carcinoma treated with nivolumab.

Noboru Nakaigawa - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Comparison of adverse event costs of nivolumab combined with ipilimumab versus sunitinib for previously untreated metastatic renal cell carcinoma.

Keith Betts - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Nivolumab

Roles of an immune-check point inhibitor (nivolumab) in heavily pretreated and platinum-resistant gynecologic cancers.

Yoshihiro Kikuchi - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Survival with nivolumab therapy in recurrent/advanced squamous cell head and neck carcinoma. A single center experience.

Ana Laura Ortega Granados - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Stereotactic body radiotherapy to extend the clinical benefit of PD-1 inhibitors in recurrent/metastatic nasopharyngeal carcinoma.

Yu Chen - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Immunomodulation by the combination of ipilimumab and nivolumab neoadjuvant to (salvage) surgery in advanced or recurrent head and neck carcinoma, IMCISION, an investigator-initiated phase-Ib/II trial (N16IMC, NCT03003637).

Charlotte L. Zuur - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Lung cancer immunotherapy outcomes in Hispanic patients.

Luis E. Raez - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Use of immunotherapy (IO) supplied free of charge to cancer patients.

Rajiv Agarwal - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Cost-effectiveness analysis of nivolumab and apatinib in third-line gastric cancer therapy.

Jiajia Yuan - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Allogeneic hematopoietic stem celltransplant (HSCT) after checkpoint inhibitors (ChIs) in classic Hodgkin lymphoma (cHL): Outcome and safety in pooled analysis.

Reyad Dada - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Next-generation-sequencing of advanced melanoma: Which genetic alterations have an impact on systemic therapy response?

Andrea Forschner - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

CTLA-4 and PD-1 inhibition in metastatic uveal melanoma: A single center experience.

Vidhya Karivedu - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Discontinuation of anti-PD-1 mAb after complete response in advanced melanoma pts.

Philippe Saiag - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Emergent renal and hepatic dysfunction (dys) in a real-world cohort of advanced melanoma (aMel) patients (pts) receiving first line (1L) immune checkpoint inhibitors (ICIs).

Susan Spillane - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

T-cell biological aging in melanoma: Impact on immunotherapeutic discontinuation.

Christin Elizabeth Burd - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF+ MM) patients receiving first-line (1L) treatment with dabrafenib/trametinib (D+T) v ipilimumab/nivolumab (I+N) and nivolumab or pembrolizumab (N/P) monotherapy at US-based community oncology practices.

Bruce A. Feinberg - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Using real world data to evaluate overall survival in PD1-treated vs. standard of care metastatic melanoma patients.

Purvi Dev-Vartak - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Filters

2342 Abstracts